The Certificate of Analysis for Research Peptides: What It Is

Before touching any peptide compound, the one document a researcher should ask for above all others is the Certificate of Analysis (CoA). It is the formal, batch-specific record that tells you what the vial genuinely holds — its identity, its purity, and its analytical fingerprint. In this guide we set out what a CoA contains, why it is so central to research integrity, and how Reta Research makes sure every batch it supplies is independently verified before it ever reaches UK researchers.

A Certificate of Analysis: what it is

A Certificate of Analysis (CoA) is a formal document, issued either by a manufacturer or by an independent testing laboratory, that certifies a particular batch of material meets set quality specifications. Where research peptides are concerned, the CoA records analytical test results — among them confirmation of identity, determination of purity, and the physical characteristics of the compound being examined [1].

A CoA is not a generic product specification sheet; it is batch-specific, reporting results from the very lot you are receiving rather than a theoretical average. A standard CoA carries the peptide's name, its sequence, the batch or lot number, the purity percentage, the analytical methods applied (HPLC and mass spectrometry, for instance), the storage conditions, and the credentials of the issuing laboratory [2].

The bottom line

A CoA is the proof that the peptide in your vial is what the label claims — and that it is pure enough to yield reliable, reproducible research results.

Why CoAs are essential to research integrity

Peptides serve as precision instruments in biochemical assays, receptor binding studies, cell signalling research and preclinical models. The scientific integrity of that work hinges on knowing — with documented certainty — exactly which compound is under study [3].

Because impurity profiles shift from one synthesis batch to the next, they inject variability into experiments. Holding purity consistently at ≥99% trims that batch-to-batch variation and underpins longitudinal studies as well as comparisons across laboratories [4]. In sensitive receptor-binding or cell-signalling assays, even 1–2% of contaminating material can bring in serious confounding variables — precisely the sort of impurities that, when left undocumented, quietly undo weeks of laboratory effort [5].

≥99%
Purity threshold for research grade
2
Minimum analytical methods (HPLC + MS)
ISO 17025
Benchmark laboratory accreditation

What goes into a peptide CoA

A correctly issued CoA sets out a defined group of fields that, taken together, form a full analytical fingerprint of the batch. Published guidance treats the following sections as essential [1][6]:

Should any of these fields be absent or generic, the document is not really working as a CoA — it is nearer to a marketing sheet.

HPLC and mass spectrometry made clear

Two analytical methods sit at the core of every credible peptide CoA, and they answer two separate yet complementary questions [4][7]:

High-Performance Liquid Chromatography (HPLC)

HPLC pulls a sample's components apart by driving it through a column under high pressure. The standard for assessing peptide purity is reversed-phase HPLC using C18 columns with UV detection at 214–220 nm [8]. The method works out purity as the main peak area divided by the total peak area — settling the question: how much of what sits in the vial is actually the target compound?

Mass Spectrometry (MS or LC-MS)

Mass spectrometry confirms a compound's molecular weight by measuring its mass-to-charge ratio once it has been ionised. Published guidelines treat mass spectrometry as the definitive identity test for synthetic peptides [1]. The spectrum it produces reveals the molecular ion peak, which can be lined up directly against the theoretical mass worked out from the peptide's elemental composition. MS settles a different question: is this molecule really the compound we were expecting?

Why both methods, not one

HPLC tells you how pure a sample is. Mass spectrometry tells you what that sample really is. A vial might be 99% pure of the wrong compound — and only HPLC and MS used together close off that possibility.

Purity standards: the real meaning of ≥99%

For the bulk of research uses, ≥98% purity (as measured by HPLC) is taken to be the research-grade standard. Premium suppliers aim higher, at ≥99% purity with impurities under 1% — impurities that include truncated sequences left by incomplete synthesis, deletion variants, dimers, and oxidation products [8][9].

Small though it may be, the remaining fraction is not inert. It generally comprises synthesis by-products that can resemble the target peptide structurally and, as a result, engage the same receptors or pathways. That is exactly why ≥99% purity has become the benchmark for peptides used in receptor-pharmacology, metabolic signalling and preclinical model research.

Independent testing versus in-house testing

CoAs do not all carry equal evidential weight. A document drawn up by the very company that synthesised the peptide is fundamentally different from one produced by an independent laboratory that has no commercial tie to the supplier.

Third-party CoAs from accredited laboratories — above all those holding ISO/IEC 17025 accreditation, the international standard for the competence of testing laboratories — carry considerably more weight precisely because they are independent of the supplier [10][11]. In-house testing is fine where proper QC facilities are in place, yet third-party verification adds a further layer of assurance that the data is genuine and the methods have been properly validated.

The way Reta Research verifies each batch

At Reta Research, each batch of research peptides that reaches our UK warehouse goes off for independent third-party analysis before a single unit is put up for sale. Three principles shape our verification workflow:

Once the laboratory sends back its certificate, the verified CoA goes up on our Quality Testing page — which means the documentation researchers see always matches the batch currently in circulation, never leftover data from an earlier lot.

Warning signs worth watching for

Not every document that carries the words "Certificate of Analysis" actually qualifies as one. The warning signs below ought to trigger a closer look before you rely on a peptide for research [9][12]:

Checking the CoA for your peptide

The verified CoA for every batch Reta Research supplies is published openly. To look up the certificate for a peptide you are working with:

  1. Head to the Reta Research Quality Testing page.
  2. Filter the table by product name, by laboratory, or by testing date.
  3. Select View Certificate to open the verified HPLC and mass spectrometry data.
  4. Should you want written confirmation of the batch tied to your particular order, get in touch through our contact form with your order number and we will send back the matching certificate.

Each certificate we publish can also be viewed openly and cross-checked, so the HPLC and mass spectrometry results always correspond to the batch in circulation — see them for yourself on our Quality Testing page at retaresearch.co/pages/quality-testing before you begin.

View verified Certificates of Analysis

Each batch independently tested by accredited third-party laboratories. HPLC and mass spectrometry verified — all published openly on a single page.

View Quality Testing

References

  1. International Organization for Standardization. ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. iso.org/standard/66912.html
  2. U.S. Food and Drug Administration. Laboratory Manual of Quality Policies (ISO 17025 Requirements). fda.gov
  3. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6A: Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. 2000. ich.org
  4. International Council for Harmonisation. ICH Q2(R1): Validation of Analytical Procedures: Text and Methodology. ich.org
  5. United States Pharmacopeia. USP General Chapter <621> — Chromatography. usp.org
  6. United States Pharmacopeia. USP General Chapter <1225> — Validation of Compendial Procedures. usp.org
  7. Mant CT, Hodges RS. HPLC Analysis and Purification of Peptides. Methods in Molecular Biology. 2007;386:3–55. PMID: 18604941. pubmed.ncbi.nlm.nih.gov/18604941
  8. Steen H, Mann M. The ABC's (and XYZ's) of peptide sequencing. Nature Reviews Molecular Cell Biology. 2004;5(9):699–711. nature.com/articles/nrm1468
  9. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:2–30. PMID: 24909775. pubmed.ncbi.nlm.nih.gov/24909775
  10. Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. Journal of Peptide Science. 2009;15(11):697–710. PMID: 19549937. pubmed.ncbi.nlm.nih.gov/19549937
  11. Wätzig H, Oltmann-Norden I, Steinicke F, et al. Regulatory Guidelines for the Analysis of Therapeutic Peptides and Proteins. Journal of Separation Science. 2025. PMC11806371. pmc.ncbi.nlm.nih.gov/PMC11806371
  12. U.S. Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin — Guidance for Industry. 2021. fda.gov
Research disclaimer: Everything Reta Research sells is strictly for in-vitro laboratory research. None of it is intended for human or veterinary use, for consumption, or for self-administration. Compounds must be handled by qualified professionals within a suitable laboratory environment. None of the products referred to here has been assessed by the MHRA or any regulatory authority for therapeutic use.